ES3014398T3 - Compositions for treating pathological calcification and ossification - Google Patents

Compositions for treating pathological calcification and ossification Download PDF

Info

Publication number
ES3014398T3
ES3014398T3 ES14751154T ES14751154T ES3014398T3 ES 3014398 T3 ES3014398 T3 ES 3014398T3 ES 14751154 T ES14751154 T ES 14751154T ES 14751154 T ES14751154 T ES 14751154T ES 3014398 T3 ES3014398 T3 ES 3014398T3
Authority
ES
Spain
Prior art keywords
npp1
polypeptide
npp4
mutant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14751154T
Other languages
English (en)
Spanish (es)
Inventor
Demetrios Braddock
Ronald Albright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES3014398T3 publication Critical patent/ES3014398T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES14751154T 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification Active ES3014398T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764297P 2013-02-13 2013-02-13
US201361904786P 2013-11-15 2013-11-15
PCT/US2014/015945 WO2014126965A2 (en) 2013-02-13 2014-02-12 Compositions and methods for treating pathological calcification and ossification

Publications (1)

Publication Number Publication Date
ES3014398T3 true ES3014398T3 (en) 2025-04-22

Family

ID=51354667

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14751154T Active ES3014398T3 (en) 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification

Country Status (6)

Country Link
US (7) US9744219B2 (OSRAM)
EP (2) EP2956163B1 (OSRAM)
JP (4) JP6894664B2 (OSRAM)
ES (1) ES3014398T3 (OSRAM)
PL (1) PL2956163T3 (OSRAM)
WO (1) WO2014126965A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
USRE49529E1 (en) 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US20180371434A1 (en) * 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
AU2017306549A1 (en) * 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
WO2019217373A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
CN116322742A (zh) * 2020-07-02 2023-06-23 依诺兹梅制药公司 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
WO2022076848A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US20020183276A1 (en) * 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011113027A2 (en) * 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Ｎｐｐ１ 융합 단백질
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
USRE49529E1 (en) * 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Also Published As

Publication number Publication date
JP2021143202A (ja) 2021-09-24
US9913881B2 (en) 2018-03-13
US20220152163A1 (en) 2022-05-19
US20150359858A1 (en) 2015-12-17
EP4523757A2 (en) 2025-03-19
JP2024026704A (ja) 2024-02-28
US20170354719A1 (en) 2017-12-14
US20200237882A1 (en) 2020-07-30
JP7420766B2 (ja) 2024-01-23
HK1214952A1 (en) 2016-08-12
EP4523757A3 (en) 2025-07-16
JP2019196392A (ja) 2019-11-14
US20170333533A1 (en) 2017-11-23
JP6894664B2 (ja) 2021-06-30
WO2014126965A3 (en) 2014-10-09
EP2956163A4 (en) 2017-03-22
EP2956163A2 (en) 2015-12-23
JP6944977B2 (ja) 2021-10-06
US20170252414A1 (en) 2017-09-07
US10624958B2 (en) 2020-04-21
US11266722B2 (en) 2022-03-08
WO2014126965A2 (en) 2014-08-21
EP2956163B1 (en) 2024-11-27
US10052367B2 (en) 2018-08-21
JP2016509023A (ja) 2016-03-24
US20180318401A1 (en) 2018-11-08
PL2956163T3 (pl) 2025-04-14
US9744219B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
ES3014398T3 (en) Compositions for treating pathological calcification and ossification
ES2375490T3 (es) Métodos y composiciones para diagnosticar degeneración macular relacionada con la edad.
US9234191B2 (en) Cytotoxic ribonuclease variants
ES2510551T3 (es) Termoestabilización de proteínas
Aspatwar et al. Carbonic anhydrase related protein VIII and its role in neurodegeneration and cancer
US20180230234A1 (en) Inhibition of the complement system
ES2291010T3 (es) Enzimas fosfodiesterasas.
US20170362312A1 (en) Sodium Pump Antibody Agonists And Methods Of Treating Heart Disease Using The Same
HK40123811A (en) Compositions and methods for treating pathological calcification and ossification
ES2328448T7 (es) 16836, un miembro de la familia de la fosfolipasa c humana y sus usos.
HK1214952B (en) Compositions for treating pathological calcification and ossification
Jiang et al. Crystal structures of human C4. 4A reveal the unique association of Ly6/uPAR/α-neurotoxin domain
ES2328114T3 (es) Regulacion de la serina/treonina proteina quinasa humana de tipo wee1.
AU2003297492A1 (en) Candida kefyr cytosine deaminase